Mattias Kyhlstedt
Mattias Kyhlstedt has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Isis Lindfeldt
2 shared publicationsJim Mumper
2 shared publicationsPauline Ocaya
2 shared publications- Alexander Seibold
Abbott Diabetes Care, Wiesbaden, Germany
1 shared publication Andrius Kavaliunas
Karolinska Institutet - Department of Clinical Neuroscience
1 shared publication- Andrius Kavaliunas
Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden
1 shared publication
Latest Publications
- Open Access
- 24 April 2025
- Published by Springer Nature in Diabetologia
- Vol. 68 (8) , 1647-1656
Severe hypoglycaemia is associated with increased risk of adverse cardiovascular complications in adults with type 1 diabetes: risk mitigation using intermittently scanned continuous glucose monitoring
Aims/hypothesis: It has been proposed that severe hypoglycaemia events (SHE) may increase the risk of adverse CVD complications in adults with type 1 diabetes. The aim of this study was to evaluate the risk of CVD complications following SHE in a large cohort of adults with type 1 diabetes, and to compare the risk of post-SHE CVD complications for users of intermittently scanned continuous glucose monitoring (isCGM) vs users of blood glucose monitoring (BGM). Methods: This comparative retrospective cohort study used data from the Swedish National Diabetes Register and the Swedish National Patient Register. We identified people with type 1 diabetes who had a hospitalisation for CVD complications. Rates of hospitalisation were compared between those with an index SHE and those without, and within isCGM or BGM subgroups. The study baseline was date of the first SHE prior to the isCGM index date. Results: We identified 14,829 adults with type 1 diabetes with up to 2 years of follow-up, of which 1313 had an index SHE. In the full cohort, the relative rate of hospitalisations for CVD complications was 2.06-fold (95% CI 1.48, 2.85) in those with prior SHE. Of these 1313 participants with prior SHE, 970 were using isCGM and 343 were using BGM. Hospitalisations for post-SHE CVD complications were significantly lower for isCGM users (5.40 per 100 person-years of follow-up; 95% CI 4.59, 6.31) compared with BGM control participants (14.23 per 100 person-years of follow-up; 95% CI 11.95, 16.82), which represents a 78% relative reduction in rates of post-SHE CVD complications for isCGM users (relative rate 0.22; 95% CI 0.11, 0.43; p<0.001), after adjustment for confounders. Conclusions/interpretation: In adults with type 1 diabetes, SHE is associated with an increased risk of hospitalisation for adverse CVD complications. This risk is significantly reduced in isCGM users compared with BGM control participants. Graphical
- 24 April 2025
- Published by Springer Nature in Diabetologia
- Vol. 68 (8) , 1647-1656
Open AccessSevere hypoglycaemia is associated with increased risk of adverse cardiovascular complications in adults with type 1 diabetes: risk mitigation using intermittently scanned continuous glucose monitoring
Aims/hypothesis: It has been proposed that severe hypoglycaemia events (SHE) may increase the risk of adverse CVD complications in adults with type 1 diabetes. The aim of this study was to evaluate the risk of CVD complications following SHE in a large cohort of adults with type 1 diabetes, and to compare the risk of post-SHE CVD complications for users of intermittently scanned continuous glucose monitoring (isCGM) vs users of blood glucose monitoring (BGM). Methods: This comparative retrospective cohort study used data from the Swedish National Diabetes Register and the Swedish National Patient Register. We identified people with type 1 diabetes who had a hospitalisation for CVD complications. Rates of hospitalisation were compared between those with an index SHE and those without, and within isCGM or BGM subgroups. The study baseline was date of the first SHE prior to the isCGM index date. Results: We identified 14,829 adults with type 1 diabetes with up to 2 years of follow-up, of which 1313 had an index SHE. In the full cohort, the relative rate of hospitalisations for CVD complications was 2.06-fold (95% CI 1.48, 2.85) in those with prior SHE. Of these 1313 participants with prior SHE, 970 were using isCGM and 343 were using BGM. Hospitalisations for post-SHE CVD complications were significantly lower for isCGM users (5.40 per 100 person-years of follow-up; 95% CI 4.59, 6.31) compared with BGM control participants (14.23 per 100 person-years of follow-up; 95% CI 11.95, 16.82), which represents a 78% relative reduction in rates of post-SHE CVD complications for isCGM users (relative rate 0.22; 95% CI 0.11, 0.43; p<0.001), after adjustment for confounders. Conclusions/interpretation: In adults with type 1 diabetes, SHE is associated with an increased risk of hospitalisation for adverse CVD complications. This risk is significantly reduced in isCGM users compared with BGM control participants. Graphical
- Open Access
- 25 January 2023
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 21 (1) , 1-20
Standardising policy and technology responses in the immediate aftermath of a pandemic: a comparative and conceptual framework
Background: The initial policy response to the COVID-19 pandemic has differed widely across countries. Such variability in government interventions has made it difficult for policymakers and health research systems to compare what has happened and the effectiveness of interventions across nations. Timely information and analysis are crucial to addressing the lag between the pandemic and government responses to implement targeted interventions to alleviate the impact of the pandemic. Methods: To examine the effect government interventions and technological responses have on epidemiological and economic outcomes, this policy paper proposes a conceptual framework that provides a qualitative taxonomy of government policy directives implemented in the immediate aftermath of a pandemic announcement and before vaccines are implementable. This framework assigns a gradient indicating the intensity and extent of the policy measures and applies the gradient to four countries that share similar institutional features but different COVID-19 experiences: Italy, New Zealand, the United Kingdom and the United States of America. Results: Using the categorisation framework allows qualitative information to be presented, and more specifically the gradient can show the dynamic impact of policy interventions on specific outcomes. We have observed that the policy categorisation described here can be used by decision-makers to examine the impacts of major viral outbreaks such as SARS-CoV-2 on health and economic outcomes over time. The framework allows for a visualisation of the frequency and comparison of dominant policies and provides a conceptual tool to assess how dominant interventions (and innovations) affect different sets of health and non-health related outcomes during the response phase to the pandemic. Conclusions: Policymakers and health researchers should converge toward an optimal set of policy interventions to minimize the costs of the pandemic (i.e., health and economic), and facilitate coordination across governance levels before effective vaccines are produced. The proposed framework provides a useful tool to direct health research system resources and build a policy benchmark for future viral outbreaks where vaccines are not readily available.
- 25 January 2023
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 21 (1) , 1-20
Open AccessStandardising policy and technology responses in the immediate aftermath of a pandemic: a comparative and conceptual framework
Background: The initial policy response to the COVID-19 pandemic has differed widely across countries. Such variability in government interventions has made it difficult for policymakers and health research systems to compare what has happened and the effectiveness of interventions across nations. Timely information and analysis are crucial to addressing the lag between the pandemic and government responses to implement targeted interventions to alleviate the impact of the pandemic. Methods: To examine the effect government interventions and technological responses have on epidemiological and economic outcomes, this policy paper proposes a conceptual framework that provides a qualitative taxonomy of government policy directives implemented in the immediate aftermath of a pandemic announcement and before vaccines are implementable. This framework assigns a gradient indicating the intensity and extent of the policy measures and applies the gradient to four countries that share similar institutional features but different COVID-19 experiences: Italy, New Zealand, the United Kingdom and the United States of America. Results: Using the categorisation framework allows qualitative information to be presented, and more specifically the gradient can show the dynamic impact of policy interventions on specific outcomes. We have observed that the policy categorisation described here can be used by decision-makers to examine the impacts of major viral outbreaks such as SARS-CoV-2 on health and economic outcomes over time. The framework allows for a visualisation of the frequency and comparison of dominant policies and provides a conceptual tool to assess how dominant interventions (and innovations) affect different sets of health and non-health related outcomes during the response phase to the pandemic. Conclusions: Policymakers and health researchers should converge toward an optimal set of policy interventions to minimize the costs of the pandemic (i.e., health and economic), and facilitate coordination across governance levels before effective vaccines are produced. The proposed framework provides a useful tool to direct health research system resources and build a policy benchmark for future viral outbreaks where vaccines are not readily available.
- Open Access
- 29 November 2022
- Published by Frontiers Media SA in Frontiers in Medical Technology
- Vol. 4, 1063622
The need for action by evaluators and decision makers in Europe to ensure safe use of medical software
Digital Health Solutions (DHS) approved under the Medical Device Directive (MDD) in the European Union may be used until May 27, 2025. The regulation provides appropriate requirements for the products but lack the evaluation by an external independent organization. For many DHS, the company can make a self-certification that the requirements have been fulfilled. As demonstrated in the evaluation of smartphone-based apps for skin cancer risk assessment such products may expose the public to undue risks. The new Medical Device Regulation provides adequate control of DHS through evaluation of independent organization prior to allowing the product on the market. HTA-evaluators and those who make decisions regarding the use of DHS need to understand the associated risks with the use of products approved according to the MDD and ensure appropriate risk mitigations to ensure that the public is not exposed to undue risk. This perspective aims to inform decisionmakers about the risks associated with the delayed requirement to transition to the new MDR regulation. There is a gap in the current guidance regarding the evolving use of machine learning and artificial intelligence. With the evolving use of DHS, it is important that industry, regulators and HTA evaluators work jointly to establish the safe and effective use of DHS.
- 29 November 2022
- Published by Frontiers Media SA in Frontiers in Medical Technology
- Vol. 4, 1063622
Open AccessThe need for action by evaluators and decision makers in Europe to ensure safe use of medical software
Digital Health Solutions (DHS) approved under the Medical Device Directive (MDD) in the European Union may be used until May 27, 2025. The regulation provides appropriate requirements for the products but lack the evaluation by an external independent organization. For many DHS, the company can make a self-certification that the requirements have been fulfilled. As demonstrated in the evaluation of smartphone-based apps for skin cancer risk assessment such products may expose the public to undue risks. The new Medical Device Regulation provides adequate control of DHS through evaluation of independent organization prior to allowing the product on the market. HTA-evaluators and those who make decisions regarding the use of DHS need to understand the associated risks with the use of products approved according to the MDD and ensure appropriate risk mitigations to ensure that the public is not exposed to undue risk. This perspective aims to inform decisionmakers about the risks associated with the delayed requirement to transition to the new MDR regulation. There is a gap in the current guidance regarding the evolving use of machine learning and artificial intelligence. With the evolving use of DHS, it is important that industry, regulators and HTA evaluators work jointly to establish the safe and effective use of DHS.
- 1 December 2020
- Published by Elsevier in Health Policy and Technology
- Vol. 9 (4) , 598-612
Swedish policy analysis for Covid-19
- 1 December 2020
- Published by Elsevier in Health Policy and Technology
- Vol. 9 (4) , 598-612
Swedish policy analysis for Covid-19
- Open Access
- 12 June 2020
- Published by Elsevier in SSRN Electronic Journal
Swedish Policy Analysis for COVID-19
Introduction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged health care systems and put societies to the test in the world beyond expectations. Objective. Our aim is to describe and analyze the Swedish approach in combating the pandemic. Methods. We present and discuss data collated from various sources - published scientific studies, pre-print material, agency reports, media communication, public surveys, etc. - with specific focus on the approach itself, COVID-19 trends, healthcare system response, policy and measures overview, and implications. Results. The main intervention to manage the curve has been the general recommendations to adhere to good hand hygiene, beware of physical distance to others, to refrain from large gatherings and restrain from non-essential travel. Persons with suspected COVID-19 infection were recommended to stay at home and avoid social contacts. Additionally, visits to the elderly care homes and meetings with more than 50 people were forbidden. As a result, the healthcare system in the country has so far, never been overwhelmed. However, the relatively high mortality among the elderly, together with the vulnerability of some migrants, points out the drawbacks. Conclusions. Many countries have both marveled and criticized the Swedish strategy that is formed in a close partnership between the government and the society based on a mutual trust giving the responsibility to individuals. It already highlights how much can be achieved with voluntary measures (recommendations) - something that was noticed and proposed as a future model by the World Health Organization.
- 12 June 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessSwedish Policy Analysis for COVID-19
Introduction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged health care systems and put societies to the test in the world beyond expectations. Objective. Our aim is to describe and analyze the Swedish approach in combating the pandemic. Methods. We present and discuss data collated from various sources - published scientific studies, pre-print material, agency reports, media communication, public surveys, etc. - with specific focus on the approach itself, COVID-19 trends, healthcare system response, policy and measures overview, and implications. Results. The main intervention to manage the curve has been the general recommendations to adhere to good hand hygiene, beware of physical distance to others, to refrain from large gatherings and restrain from non-essential travel. Persons with suspected COVID-19 infection were recommended to stay at home and avoid social contacts. Additionally, visits to the elderly care homes and meetings with more than 50 people were forbidden. As a result, the healthcare system in the country has so far, never been overwhelmed. However, the relatively high mortality among the elderly, together with the vulnerability of some migrants, points out the drawbacks. Conclusions. Many countries have both marveled and criticized the Swedish strategy that is formed in a close partnership between the government and the society based on a mutual trust giving the responsibility to individuals. It already highlights how much can be achieved with voluntary measures (recommendations) - something that was noticed and proposed as a future model by the World Health Organization.
- 1 June 2020
- Published by Elsevier in Health Policy and Technology
- Vol. 9 (2) , 126-128
Diagnostic and digital solutions to address the COVID-19 pandemic: The need for international collaboration to close the gap
- 1 June 2020
- Published by Elsevier in Health Policy and Technology
- Vol. 9 (2) , 126-128
Diagnostic and digital solutions to address the COVID-19 pandemic: The need for international collaboration to close the gap